Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Aminotransferases disorders associated with venous thromboembolic events in pati...
Journal Information
Share
Share
Download PDF
More article options
Letters to the editor
DOI: 10.1016/j.aohep.2021.100334
Open Access
Pre-proof, online 21 February 2021
Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19
Visits
...
Amer Hamadéa,
Corresponding author
hamadea@ghrmsa.fr

Corresponding author.
, Bastien Woehla, Marjolaine Talbota, Naouel Bensalaha, Pierre Michela, Golnaz Obringera, Michèle Lehn-Hogga, Nathalie Buschenriedera, Mahdi Issab, Jonathan Touscha, Dominique Stephanc, Lucas Jamberta
a Service de Médecine Vasculaire, GHRMSA, Hôpital Emile Muller, 20, Rue du Dr Laennec, 68051 Mulhouse, France
b Service de Chirurgie Digestive, GHRMSA, Hôpital Emile Muller, Mulhouse, France
c Service d'Hypertension et de Maladies Vasculaires, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Descriptive analysis.
Table 2. Patient characteristics.
Show moreShow less
Full Text
Dear Editor,

Zhu et al. published an interesting correspondence [1] regarding the article we published in October 2020 in Annals of Hepatology [2].

We revised our statistics using the same software: for ALT (normal <61IU / L) mean 57.3 ± 36.1 UI/L : 48.9 ± 31.5 in patients without venous thrombo embolism (VTE) event (PNOVTE) versus 91.5 ± 71.0 in patients with VTE (PVTE), p value = 0.059. The p value are the same for the other parameters: D-dimer (in our cohort, only 40 patients/46 had a D-dimer sampling): mean 2914 ± 5362 ng/l : 1779 ± 2941 in PNOVTE versus 7315 ± 9550 in PVTE p = 0.021. For NT-proBNP (39 patients of 46 had a NT-proBNP sampling:mean 2388 ± 5361 pg /mL, 2879 ± 5927 in PNOVTE versus 2735 ± 6227 in PVTE, p = 0.52. For CPK, only 20 patients/46 had a CPK sampling : mean 124 ± 83.3 UI/L, 134 ± 83.3 in PNOVTE versus 46.5 ± 19.1 in PDVT p = 0.079 (Tables 1 and 2). The univariate analysis was realized with Mann-Whitney test. P values less than 0.05 were considered to indicate statistical significance.

Table 1.

Descriptive analysis.

  mean (sd)  median [Q25-75]  min  max 
ALT  57.3 (36.1)  46.5 [28.2; 72.8]  11.0  149  46/46 
NT-proBNP  2388 (5361)  362 [128; 1192]  30.0  24514  39/46 
CPK  122 (80.0)  116 [62.2; 135]  33.0  328  20/46 
D-dimer  2914(5362)  986 [572; 2079]  132  25000  40/46 
Table 2.

Patient characteristics.

VARIABLE  Total 46 patientsmean  36 NO VTEmean  10 VTEmean  P value 
Age (years)  67.2 ± 12.0  67.1 ± 12.1  67.6 ± 12.4  0.79 
F (n,%) M (n,%)  24 (52%) 22 (48%)  20 (56%) 16 (44%)  4 (40%) 6 (60%)  0.48 
AST (<37UI/L)  50.3 ± 34.1  50.4 ± 34.7  50.1 ± 33.7  0.94 
ALT (<61UI/L)  57.3 ± 36.1  48.9 ± 31.5  91.5 ± 71.0  0.059 
Total Biluribin (1 − 17um/L)  9.90 ± 4.01  10.1 ± 4.41  9.40 ± 2.84 
D-dimer (<500 ng/mL)  2914 ± 5362  1779 ± 2941  7315 ± 9550  0.021 
GammaGT (15 − 85 UI/L)  136 ± 152  128 ± 155  173 ± 145  0.41 
Alkaline phosphatase (45 − 117 UI/L)  149 ± 206  159 ± 230  114 ± 70.7  0.71 
CRP (0 − 3 mg/L)  83.3 ± 61.8  69.7 ± 53.1  110 ± 72.8  0.11 
GF >90 ml/min)  78.6 ± 30.0  78.1 ± 31.1  80.7 ± 26.5 
BMI (kg/m227.9 ± 4.14  27.8 ± 4.03  28.3 ± 4.74  0.72 
aPTT (0.86 − 1.20)  1.09 ± 0.298  1.09 ± 0.236  1.10 ± 0.456  0.19 
NT-proBNP (<194 pg/mL)  2388 ± 5361  2879 ± 5927  2735 ± 6227  0.52 
CPK (26 − 192 UI/L)  124 ± 83.3  134 ± 83.3  46.5 ± 19.1  0.079 
Hemoglobin (13.5 − 16.9 g/dL)  12.7 ± 2.05  12.5 ± 1.87  13.2 ± 2.78  0.23 
LDH (57 − 241 UI/L)  360 ± 151  361 ± 159  356 ± 134 
Lymphocyes (1.26 − 3.35 × 10.9/L)  1.28 ± 1.39  1.28 ± 1.57  1.27 ± 0.475  0.16 
Platelets (166 − 308 × 10.9/L)  280 ± 108  280 ± 108  301 ± 87.1  0.36 
WBC (3.91 − 10.9 × 10.9/L)  7.85 ± 4.08)  6.83 ± 3.52  11.2 ± 4.15  <0.01 
Prothrombin time %  78.3 ± 13.9  78.3 ± 15.0)  78.4 ± 10.7  0.91 
Home ICU Follow-up care Death  8 (18%) 4 (11%) 3(6.5%)  22(63%) 6(17%) 4(11%) 2(8.6%)  7 (70%) 2(20%) 0 (0%) 1(10%)  0.87 
Hypertension  25 (54.3%)  22(5.5%)  3(30%)   
Diabetes  7 (15.2%)  7(19.4%)  0(0%)   
Dyslipidemia  11 (24%)  10 (27.8%)  1(10%)   
Digestive sypmtoms  4 (8.7%)  3 (8.3%)  1 (10%)   
History/liver diseases (n,%)  0 (0%)  0(%)  0(%)   
Smoking  10 (21.7%)  10 (27.8%)  0(0%)   
Lymphopenia  29 (63%)  24(67%)  5(50%)   
Active cancer  0 (0%)  0 (0%)  0 (0%)   
History of cancer (n,%)  3 (6.5%)  3 (8.3%)  0(0%)   
History of VTE (n,%)  3 (6.5%)  2(5.5%)  1(10%)   
Chronic Renal Failure  5 (8.7%)  5 (13.9%)  0(0%)   
Haemodialysis  2(4.3%)  2(5.6%)  0(0%)   
Sleep Apnea Syndrome  6 (13%)  4 (11%)  2(20%)   
Septicaemia  0 (0%)  0 (0%)  0 (0%)   

BMI = Body mass index. CRP = C-reactive protein. LDH = Lactic aciddehydrogenase. ICU = Intensive Care Unit. NT-proBNP = N-terminal prohormone brain natriuretic peptide. aPTT = Activated partial thromblastine time. WBC = White blood cells. CPK = creatine phosphokinase.

Declaration of funding interests

None.

Conflict of interest

The authors have no conflict of interest to declare.

References
[1]
X. Zhu, X. Li.
Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19.
Ann Hepatol., 23 (2021),
[2]
A. Hamadé, B. Woehl, M. Talbot, N. Bensalah, P. Michel, O. Obringer, et al.
Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19.
Ann Hepatol., (2020),
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos